全文获取类型
收费全文 | 399篇 |
免费 | 30篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 33篇 |
基础医学 | 33篇 |
口腔科学 | 6篇 |
临床医学 | 41篇 |
内科学 | 58篇 |
皮肤病学 | 4篇 |
神经病学 | 4篇 |
特种医学 | 135篇 |
外科学 | 21篇 |
综合类 | 6篇 |
预防医学 | 10篇 |
药学 | 26篇 |
1篇 | |
肿瘤学 | 60篇 |
出版年
2021年 | 8篇 |
2020年 | 7篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 5篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 16篇 |
2011年 | 5篇 |
2010年 | 4篇 |
2009年 | 10篇 |
2008年 | 12篇 |
2007年 | 13篇 |
2006年 | 15篇 |
2005年 | 5篇 |
2004年 | 5篇 |
2003年 | 9篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 9篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 26篇 |
1995年 | 15篇 |
1994年 | 21篇 |
1993年 | 16篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 18篇 |
1988年 | 15篇 |
1987年 | 19篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 9篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1977年 | 6篇 |
1976年 | 9篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1968年 | 1篇 |
1966年 | 2篇 |
1965年 | 1篇 |
排序方式: 共有439条查询结果,搜索用时 46 毫秒
71.
KJ Champion C Bunag AL Estep JR Jones CH Bolt RC Rogers KA Rauen DB Everman 《Clinical genetics》2011,79(5):468-474
Champion KJ, Bunag C, Estep AL, Jones JR, Bolt CH, Rogers RC, Rauen KA, Everman DB. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. BRAF, the protein product of BRAF, is a serine/threonine protein kinase and one of the direct downstream effectors of Ras. Somatic mutations in BRAF occur in numerous human cancers, whereas germline BRAF mutations cause cardio‐facio‐cutaneous (CFC) syndrome. One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. However, a germline mutation affecting codon 600 has never been described. Here, we present a patient with CFC syndrome and a de novo germline mutation involving codon 600 of BRAF, thus providing the first evidence that a pathogenic germline mutation involving this critical codon is not only compatible with development but can also cause the CFC phenotype. In vitro functional analysis shows that this mutation, which replaces a valine with a glycine at codon 600 (p.V600G), leads to increased ERK and ELK phosphorylation compared to wild‐type BRAF but is less strongly activating than the cancer‐associated p.V600E mutation. 相似文献
72.
73.
The RAF inhibitor vemurafenib has unprecedented activity in BRAF-mutant melanomas, but resistance invariably develops. As Hsp90 is required for the stability of several of the oncoproteins that mediate RAF inhibitor resistance, inhibitors of this cellular chaperone may be effective in patients with intrinsic or acquired resistance to RAF inhibitors. 相似文献
74.
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer 下载免费PDF全文
75.
Marks JL Gong Y Chitale D Golas B McLellan MD Kasai Y Ding L Mardis ER Wilson RK Solit D Levine R Michel K Thomas RK Rusch VW Ladanyi M Pao W 《Cancer research》2008,68(14):5524-5528
Genetic lesions affecting a number of kinases and other elements within the epidermal growth factor receptor (EGFR) signaling pathway have been implicated in the pathogenesis of human non-small-cell lung cancer (NSCLC). We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this pathway that could contribute to lung tumorigenesis. We have identified in 2 of 207 primary lung tumors a somatic activating mutation in exon 2 of MEK1 (i.e., mitogen-activated protein kinase kinase 1 or MAP2K1) that substitutes asparagine for lysine at amino acid 57 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells. We also screened 85 NSCLC cell lines for MEK1 exon 2 mutations; one line (NCI-H1437) harbors a Q56P substitution, a known transformation-competent allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with AZD6244. MEK1 mutants have not previously been reported in lung cancer and may provide a target for effective therapy in a small subset of patients with lung adenocarcinoma. 相似文献
76.
Sawai A Chandarlapaty S Greulich H Gonen M Ye Q Arteaga CL Sellers W Rosen N Solit DB 《Cancer research》2008,68(2):589-596
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) are found in a subset of patients with lung cancer and correlate with response to EGFR tyrosine kinase inhibitors (TKI). Resistance to these agents invariably develops, and current treatment strategies have limited efficacy in this setting. Hsp90 inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG), induce the degradation of EGFR and other Hsp90 interacting proteins and may thus have utility in tumors dependent upon sensitive Hsp90 clients. We find that the EGFR mutations found most commonly in patients with lung adenocarcinoma who respond to EGFR TKIs are potently degraded by 17-AAG. Although the expression of wild-type EGFR was also down-regulated by 17-AAG, its degradation required higher concentrations of drug and a longer duration of drug exposure. In animal models, a single dose of 17-AAG was sufficient to induce degradation of mutant EGFR and inhibit downstream signaling. 17-AAG treatment, at its maximal tolerated dose, caused a significant delay in H3255 (L858R EGFR) xenograft growth but was less effective than the EGFR TKI gefitinib. 17-AAG alone delayed, but did not completely inhibit, the growth of H1650 and H1975 xenografts, two EGFR mutant models which show intermediate and high levels of gefitinib resistance. 17-AAG could be safely coadministered with paclitaxel, and the combination was significantly more effective than either drug alone. These data suggest that Hsp90 inhibition in combination with chemotherapy may represent an effective treatment strategy for patients whose tumors express EGFR kinase domain mutations, including those with de novo and acquired resistance to EGFR TKIs. 相似文献
77.
78.
Hannah Maynard BS Zsofia K. Stadler MD Michael F. Berger MD David B. Solit MD Michele Ly BS Maeve A. Lowery MD Diana Mandelker MD Liying Zhang MD Emmett Jordan MD Imane El Dika MD Yelena Kemel MS Marc Ladanyi MD Mark E. Robson MD Eileen M. O’Reilly MD Ghassan K. Abou-Alfa MD MBA 《Cancer》2020,126(9):1995-2002
79.
Intracranial meningiomas: high-field MR imaging 总被引:6,自引:0,他引:6
Spagnoli MV; Goldberg HI; Grossman RI; Bilaniuk LT; Gomori JM; Hackney DB; Zimmerman RA 《Radiology》1986,161(2):369
80.